Skip to main content
OpenTrials
Completed

NCT Number: NCT02657265

SpineJack® Versus Conservative Treatment Study (SPICO Study)

This study will compare two standard treatments in acute stable traumatic vertebral fractures (types A1 and A3.1 by Magerl Classification). The two treatments are as follows:

1. SpineJack® system 2. Conservative Orthopedic Management consisting of brace and pain medication.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital Jean Minjoz Besancon, Besançon, France

Loading trial locations.

About this study

100 subjects (18 to 60 years old) will be enrolled (1:1) with one to two painful traumatic fractures, non-pathological (types A1 and A3.1 by Magerl Classification).

Subjects will be followed at admission, procedure, discharge, 1 month, 3 months, 12 months and 24 months post Vertebral Compression Fracture (VCF) reduction procedure or the set-up of the brace.

The estimated enrollment period is 12 months and each patient should perform a 24 months follow-up period. Therefore, the total study duration is estimated to be 36 months for the complete study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient must have signed the consent form
  • Male or Female between 18 and 60 years old
  • One to two painful traumatic fractures, non-pathological, traumatic vertebral fracture is less than 10 days, between T11 and L5, type A1 and A3.1 according to Magerl classification. All the fractures should meet the inclusion criteria (deformity, etiology, technical possibility of performing the procedure).
  • Vertebral kyphosis angle >10°
  • Patient is eligible to treatment with brace
  • Technical feasibility of a SpineJack® procedure and brace 1 to 5 days after screening/baseline

Exclusion criteria

  • Vertebral fracture more than 10 days old
  • Spontaneous osteoporotic vertebral fracture
  • Neurological signs or symptoms related to the vertebral fracture
  • Vertebral kyphosis angle >30°
  • Active systemic or local infection at baseline
  • Patient with substance abuse
  • History of intolerance or allergic reaction to titanium or acrylic compounds
  • Fracture geometry making the insertion of the implant impossible
  • Malignant lesions
  • Any other medical illness or condition that, in the investigator's opinion, is likely to impair long-term follow-up (e.g., cancer) or greatly increase the risk of surgery*
  • Patient on long-term steroid therapy (steroid dose ≥ 30 mg /day for > 3 months)
  • Patient presenting with a non-correctable spontaneous or therapeutic coagulation disorder.
  • Non-compliant patient: Impossibility to participate in the study and to be followed-up for 2 years.
  • Participating in any other investigational study
  • Female patients who are pregnant, breastfeeding, or planning to get pregnant during the course of the study
  • Patient not affiliated to social security *: including but not limited to patients with contraindications for general anesthesia (surgeon expertise)

Treatment and study plan

SpineJack system

Device

Spine fracture management for traumatic vertebral compression fracture

Conservative management

Device

Surgical corset according to measurement's impression, rigid corset with sternal support

Primary outcomes

  1. VAS

    Time frame: 1 and 12 months follow-up

    Mean Visual Analogue Scale (VAS) back pain score at 1 and 12 months follow-up

Secondary outcomes

  1. Oswestry Disability Index

    Time frame: Screening/baseline, immediat post-op, 1, 3, 12 and 24 months

  2. EQ-5D

    Time frame: Screening/baseline, immediat post-op, 1, 3, 12 and 24 months

  3. Kyphotic angle

    Time frame: Screening/baseline, immediat post-op, 1, 3, 12 and 24 months

  4. Regional Kyphotic Angle

    Time frame: Screening/baseline, immediat post-op, 1, 3, 12 and 24 months

  5. Evaluation of safety through evaluation of adverse events

    Time frame: Screening/baseline, immediat post-op, 1, 3, 12 and 24 months

  6. Costs comparison of overall treatments

    Time frame: Screening/baseline, immediat post-op, 1, 3, 12 and 24 months

Sponsors and collaborators

Lead sponsor

Vexim SA

Industry

Collaborators

  • Statitec

Registry information

Official study title

Prospective Multicenter Randomized Study Comparing Two Standard Treatments: SpineJack® System and Conservative Orthopedic Management in Acute Traumatic Vertebral Fractures Types A1 and A3.1 According to the Magerl Classification

Important dates

Study start
2016
Primary completion
2019
Study completion
2020
First posted
Jan 15, 2016
Registry last updated
Apr 20, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.